BioXcel Therapeutics
BTAI
70 hedge funds and large institutions have $117M invested in BioXcel Therapeutics in 2020 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.
350% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 8
85% more capital invested
Capital invested by funds: $63.3M → $117M (+$53.5M)
63% more funds holding
Funds holding: 43 → 70 (+27)
0.36% more ownership
Funds ownership: 1.5% → 1.86% (+0.36%)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
7% less call options, than puts
Call options by funds: $4.06M | Put options by funds: $4.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$12M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$7.08M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.74M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$6.16M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.85M |
| 2 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$6.44M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
-$4.77M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.73M |
| 5 |
DAM
DLD Asset Management
New York
|
-$956K |
BTAI Hedge Fund Activity: Q1 2020 in Review
70 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2020, worth a combined $117M — up 85% from $63.3M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BTAI positions and 8 closed out — a net gain of 28 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $12M. The largest seller was Fidelity Investments, cutting an estimated $6.85M.
- 70 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2020, up from 43 in Q4 2019.
- Funds reported $117M of BioXcel Therapeutics stock for Q1 2020, up 85% quarter-over-quarter.
- 36 funds opened new BioXcel Therapeutics positions in Q1 2020 and 8 closed out, a net change of +28 holders.
- The largest BioXcel Therapeutics buyer in Q1 2020 was Ikarian Capital, an estimated $12M added.
- The largest BioXcel Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $6.85M sold.
Based on aggregated 13F filings for Q1 2020.